Arcutis Biotherapeutics (ARQT) Current Assets (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Current Assets of $438.1 million for Q1 2026, up 35.34% year-over-year from $323.7 million in Q1 2025, and up 6.52% quarter-over-quarter from $411.2 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Current Assets (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $438.1 million for Q1 2026.
- In Q1 2026, Current Assets rose 35.34% year-over-year to $438.1 million; the TTM figure through Mar 2026 stood at $438.1 million (up 35.34% YoY), while the FY2025 annual figure was $411.2 million, up 22.46% from the prior year.
- Current Assets for Q1 2026 stood at $438.1 million, up from $411.2 million in the prior quarter.
- The five-year high for Current Assets was $496.7 million in Q3 2022, with the low at $281.5 million in Q3 2023.
- The 5-year median for Current Assets is $358.9 million (2022), against an average of $376.1 million.
- The sharpest annual moves came in 2023 and 2024: Current Assets slumped 43.32% in 2023, then jumped 50.5% in 2024.
- Arcutis Biotherapeutics' Current Assets stood at $437.4 million in 2022, then fell by 24.46% to $330.4 million in 2023, then gained by 1.63% to $335.8 million in 2024, then advanced by 22.46% to $411.2 million in 2025, then grew by 6.52% to $438.1 million in 2026.
- Business Quant data shows ARQT's Current Assets at $438.1 million in Q1 2026, $411.2 million in Q4 2025, and $349.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 467.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 467.67 Mn |
| Mar 31, 2026 | 438.06 Mn |
| Dec 31, 2025 | 411.23 Mn |
| Sep 30, 2025 | 349.22 Mn |
| Jun 30, 2025 | 332.78 Mn |
| Mar 31, 2025 | 323.67 Mn |
| Dec 31, 2024 | 335.82 Mn |
| Sep 30, 2024 | 423.72 Mn |
| Jun 30, 2024 | 434.59 Mn |
| Mar 31, 2024 | 468.06 Mn |
| Dec 31, 2023 | 330.43 Mn |
| Sep 30, 2023 | 281.55 Mn |
| Jun 30, 2023 | 308.87 Mn |
| Mar 31, 2023 | 367.68 Mn |
| Dec 31, 2022 | 437.41 Mn |
| Sep 30, 2022 | 496.72 Mn |
| Jun 30, 2022 | 295.43 Mn |
| Mar 31, 2022 | 358.92 Mn |
| Dec 31, 2021 | 402.77 Mn |
| Sep 30, 2021 | 381.77 Mn |